{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:40:01Z","timestamp":1791258001112,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFB3800900"],"award-info":[{"award-number":["2021YFB3800900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52273251"],"award-info":[{"award-number":["52273251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52473264"],"award-info":[{"award-number":["52473264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jconrel.2025.113934","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:57:54Z","timestamp":1749157074000},"page":"113934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antibody-mediated ratiometric delivery of FLT3 and CDK4\/6 dual inhibitors for targeted treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"384","author":[{"given":"Zhenzhen","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113934_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113934_bb0010","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.113934_bb0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.113934_bb0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113934_bb0025","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.113934_bb0030","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41551-020-00624-6","article-title":"Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.113934_bb0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/d41573-019-00142-4","article-title":"The acute myeloid leukaemia market","volume":"19","author":"Schaefer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113934_bb0040","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025, CA Cancer","volume":"75","author":"Kantarjian","year":"2025","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.jconrel.2025.113934_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.113934_bb0055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113934_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0070","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.113934_bb0075","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.3390\/cancers14174315","article-title":"Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure","volume":"14","author":"Capelli","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.113934_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12935-023-03000-x","article-title":"Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jconrel.2025.113934_bb0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.113934_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-022-01755-2","article-title":"Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia","volume":"37","author":"Ling","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.113934_bb0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.113934_bb0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10928-014-9393-x","article-title":"FLT3 and CDK4\/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia","volume":"41","author":"Zhang","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2025.113934_bb0105","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2015-11-683581","article-title":"Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6","volume":"127","author":"Uras","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113934_bb0110","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","article-title":"Nanomedicine of synergistic drug combinations for cancer therapy \u2013 strategies and perspectives","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113934_bb0115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41565-022-01310-1","article-title":"Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma","volume":"18","author":"Detappe","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0120","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s40843-020-1627-4","article-title":"Co-delivery of chemotherapeutic drugs and cell cycle regulatory agents using nanocarriers for cancer therapy","volume":"64","author":"Sun","year":"2021","journal-title":"Sci. China Mater."},{"key":"10.1016\/j.jconrel.2025.113934_bb0125","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.113934_bb0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:Daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2025.113934_bb0135","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113934_bb0140","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0145","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2020.10.003","article-title":"Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation","volume":"329","author":"Gu","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113934_bb0150","first-page":"499","article-title":"Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia","volume":"21","author":"Xia","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2025.113934_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101872","article-title":"Exogenous CD38 upregulation enables high-efficacy dually cascade targeted molecular therapy of leukemia","volume":"50","author":"Du","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.113934_bb0160","doi-asserted-by":"crossref","first-page":"2209984","DOI":"10.1002\/adma.202209984","article-title":"Exogenous antigen upregulation empowers antibody targeted nanochemotherapy of leukemia","volume":"35","author":"Yue","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113934_bb0165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","article-title":"Daratumumab: First global approval","volume":"76","author":"McKeage","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113934_bb0170","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1182\/blood-2023-189132","article-title":"Phase I study of FT538 + daratumumab for treatment of r\/r AML","volume":"142","author":"Maakaron","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113934_bb0175","doi-asserted-by":"crossref","first-page":"2007787","DOI":"10.1002\/adma.202007787","article-title":"Daratumumab immunopolymersome-enabled safe and CD38-targeted chemotherapy and depletion of multiple myeloma","volume":"33","author":"Yu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113934_bb0180","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113934_bb0185","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.18735","article-title":"Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells","volume":"201","author":"Xie","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0190","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/leu.2017.257","article-title":"Tyrosine kinase inhibition increases the cell surface localization of FLT3-itd and enhances FLT3-directed immunotherapy of acute myeloid leukemia","volume":"32","author":"Reiter","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.113934_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.113934_bb0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.113934_bb0205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41375-023-02131-4","article-title":"FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia","volume":"38","author":"Sung","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.113934_bb0210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41580-019-0143-1","article-title":"The roles of DNA, RNA and histone methylation in ageing and cancer","volume":"20","author":"Michalak","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0215","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.113934_bb0225","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1200\/jco.2004.22.90140.6711","article-title":"Acute myeloid leukemia (AML): a study of 516 patients","volume":"22","author":"Kumar","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113934_bb0230","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2019-127099","article-title":"Clinical utility of flow cytometry immunophenotyping in acute myeloid leukemia","volume":"134","author":"Oliveira","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113934_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.stem.2017.12.014","article-title":"Chewing through roots: how leukemia invades and disrupts the bone marrow microenvironment","volume":"22","author":"Tamplin","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jconrel.2025.113934_bb0240","doi-asserted-by":"crossref","first-page":"eaao5726","DOI":"10.1126\/scitranslmed.aao5726","article-title":"Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone","volume":"10","author":"Dondossola","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113934_bb0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41556-019-0437-8","article-title":"Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair","volume":"22","author":"Yahara","year":"2020","journal-title":"Nat. Cell Biol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:01:22Z","timestamp":1779512482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925005541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":49,"alternative-id":["S0168365925005541"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113934","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-mediated ratiometric delivery of FLT3 and CDK4\/6 dual inhibitors for targeted treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113934"}}